Panoramic Visualization of Circulating MicroRNAs Across Neurodegenerative Diseases in Humans

0301 basic medicine 03 medical and health sciences Gene Ontology Genome, Human Gene Expression Profiling Down-Regulation Humans Neurodegenerative Diseases Circulating MicroRNA Article Phylogeny 3. Good health
DOI: 10.1007/s12035-019-1615-1 Publication Date: 2019-04-30T12:19:54Z
ABSTRACT
Neurodegenerative diseases (NDs) such as Alzheimer's disease (AD), Parkinson's (PD), multiple sclerosis (MS), amyotrophic lateral (ALS), and dementia pose one of the greatest health challenges this century. Although these NDs have been looked at single entities, underlying molecular mechanisms never collectively visualized to date. With advent high-throughput genomic proteomic technologies, we now opportunity visualize in a whole new perspective, which will provide clear understanding primary secondary events vital achieving final resolution guiding us treatment strategies possibly treat together. We created knowledge base all microRNAs known be differentially expressed various body fluids ND patients. then used several bioinformatic methods understand functional intersections differences between AD, PD, ALS, MS. These results unique panoramic view possible MS, ALS level microRNA their cognate genes pathways, along with entities that unify separate them. While signatures were apparent for each ND, observation our study was hsa-miR-30b-5p overlapped four NDS, has significant roles described across NDs. Furthermore, also show evidence convergence miRNAs associated regulation represented pathways included fatty acid synthesis metabolism, ECM receptor interactions, prion diseases, signaling critical neuron differentiation survival, underpinning relevance Envisioning group together allowed propose ways utilizing circulating biomarkers visualizing diverse more holistically . The insights gained through discovery ND-associated miRNAs, overlapping on strongly implicated neurodegenerative processes can prove immensely valuable identifying generation biomarkers, development into therapeutics.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (179)
CITATIONS (32)